Recently, a human monoclonal antibody targeting TNFα, golimumab, was shown to improve endogenous insulin production and reduce exogenous insulin requirement in individuals with recent onset T1D [175]. The gene discussed is TNF; the disease is type 1 diabetes mellitus.